Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joe Payne - President and Chief Executive Officer, Director of the Board Andy Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Lili Nsongo - Leerink Yasmeen Rahimi - Piper Sandler Evan Wang - Guggenheim Securities Myles Minter - William Bl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period Commission File Number 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of Registrant as specified in its Charter) Delaware 32-0595345 (State or other jurisdic ...

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress Phase 2 interim data for ARCT-032 (CF) & ARCT-810 (OTCD) on track for Q2 2025 Meiji Seika Pharma and ARCALIS received MHLW approval for commercial manufacturing of KOSTAIVE® Meiji Seika Pharma Submitted Application for Two-Dose Vial of KOSTAIVE® KOSTAIVE® U.S. BLA filing anticipated 2025 Investor conference call at 4:30 p.m. ET today SAN DIEGO--(BUSINESS WIRE)--March 6, 2025-- Arcturus Therapeutics Hol ...

- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA COVID-19 vaccines in clinical trialsWALTHAM, Mass. and SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE ® (ARCT ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joseph Payne - President and CEO Andrew Sassine - CFO Pad Chivukula - CSO & COO Conference Call Participants Lili Nsongo - Leerink Whitney Ijem - Canaccord Genuity Evan Wang - Guggenheim Securities Myles Minter - William Blair Samantha Schaeffer - Cantor Fitzgerald Yale Jen - Laidlaw & Company Yigal Nochomovitz - Citi ...

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 62.86%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $1.85 per share when it actually produced a loss of $0.64, delivering a surprise of 65.41%.Over the last four quarters, the ...

cs UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ARCT The NASDAQ Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ...

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress Cystic Fibrosis and OTC Deficiency Phase 2 studies on track for POC data in first half of 2025 $25 Million commercial milestone achieved with first sale of KOSTAIVE® in Japan KOSTAIVE® European CHMP opinion expected December Positive results from multiple Phase 3 studies support KOSTAIVE® U.S. BLA filing in H1 2025 Superior 12-month durability results from Phase 3 study of KOSTAIVE® published in The Lancet Infectious D ...

We expect investors to focus on the launch plans of Arcturus Therapeutics Holdings Inc.’s (ARCT) self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, Kostaive (ARCT-154), and updates on the pipeline when it reports third-quarter 2024 results on Nov. 7, after market close.The Zacks Consensus Estimate for revenues is pegged at $49.2 million.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Let's see how things might have shaped up for the quarter to be reported.Factors to Note Ahead of ARCT ...